News

Agilis Steadily Advances Angelman Gene Therapy Development

Agilis Biotherapeutics said its Angelman syndrome gene therapy development is on track, with initial animal studies making way for tests needed before the therapy can be tried in humans. The Cambridge, Massachusetts, company announced that it plans to choose a lead candidate before consulting the U.S. Food and Drug Administration…

Genomic Recycling May Help Explain Our Unique Non-Coding Genome

Throughout evolution, genomic recycling of protein-coding genes gave rise to part of non-coding genes within our genome, known as long non-coding RNAs, or lncRNAs, a Weizmann Institute of Science study suggests. The findings will help scientists understand the role of lncRNAs in healthy and diseased conditions, such as Angelman…

Spanish Study Examines Role of Age, Gender in Hospitalizations

An analysis of the most common causes of hospitalization among patients with Angelman syndrome reveals that they differ based on age and gender. The study, published in the Journal of Applied Research in Intellectual Disabilities, shows common healthcare needs among sub-groups of Angelman patients, which may help design tailored…